Upload
malana
View
39
Download
5
Tags:
Embed Size (px)
DESCRIPTION
Click to enlarge. Click to enlarge. Click to enlarge. Click to enlarge. Alemtuzumab Infusion-associated Reactions and Management in Multiple Sclerosis. Before Infusion. During Infusion. After Infusion. Lori Mayer, 1 Lise Casady, 2 Gail Clayton, 3 Pedro Oyuela, 4 David H. Margolin 4 - PowerPoint PPT Presentation
Citation preview
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Alemtuzumab Infusion-associated Reactions and Management in Multiple Sclerosis Lori Mayer,1 Lise Casady,2 Gail Clayton,3 Pedro Oyuela,4 David H. Margolin4
1Central Texas Neurology Consultants, MS Clinic of Central Texas, Round Rock, TX, USA; 2University of South Florida, Tampa, FL, USA; 3Helen Durham Centre, University Hospital of Wales, Cardiff, UK; 4Genzyme, a Sanofi company, Cambridge, MA, USA
Presented at the Infusion Nurses Society 2014 Annual Convention and Industrial Exhibition, May 3–8, 2014, Phoenix, AZ
Figure 1. IAR Management Strategies During Alemtuzumab Clinical Trials
Urticarial rash
Non-selective antihistamine (IV for rapid onset; some administered IM)
Bronchospasm/anaphylactoid reactions
Epinephrine (0.3 mg IV or IM) Beta-adrenergic agonist inhaler for
bronchospasm Non-selective antihistamine for anaphylactoid
reaction (IV for rapid onset; some administered IM)
Oxygen
Hypotension/bradycardia
IV fluid (normal saline) bolus (500 cc) + oral hydration
Epinephrine (0.3 mg IV or IM) Atropine for bradycardia
Headache, myalgia, rigors
Analgesic (eg, acetaminophen) Narcotic analgesia Triptan (for more persistent or migrainous
headache)
Patient education
• Risks and benefits of alemtuzumab
• Detailed description of potential AEs, including short-term (IARs, infections) and long-term effects (autoimmune events)
• Counseled that IARs are mostly mild-to-moderate in severity, transient, and manageable
• Educated about the duration of infusion and what to expect on each infusion day
Premedication
• All patients were pre-treated with methylprednisolone 1 g IV immediately prior to infusion on each of the first 3 days of any treatment course
• Pre-treatment with antihistamines, antipyretics, and/or anti-emetics was also permitted
• Mild or moderate IARs occurred in most patients despite pre-treatment
Before Infusion During Infusion After Infusion
Monitoring
• Continued monitoring for 2 hours post-infusion for potential IARs
Prescriptions
• Medications were prescribed in some cases for symptoms occurring after patients left the clinic:- Antihistamine and antipyretics for rash,
headache, or fever- Anti-emetics for nausea- Analgesics for pain- Sleep aids
Patient observation
• Hourly vital signs
• Body language indicative of possible AEs (eg, urge to void; reaching for blanket may indicate chills)
• Infusion site was regularly inspected for possible IV complications
• Adequate hydration
Infusion rate adjustment or interruption
• Infusions were typically administered over a period of 4 hours
• Infusions were interrupted and resumed at a lower rate, or discontinued, in a minority of patients
• Maximum infusion period was 8 hours
Symptomatic treatment
AE=adverse event; IAR=infusion-associated reaction; IM=intramuscular; IV=intravenous
Presented at the Infusion Nurses Society 2014 Annual Convention and Industrial Exhibition, May 3–8, 2014, Phoenix, AZ
Back to poster
Back to poster
Back to poster
Back to poster